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Abstract
Background: Although patients with Treatment Resistant Depression (TRD) often have impaired social functioning,
few studies have investigated the effectiveness of psychosocial treatment for these patients. We examined whether
adding group cognitive behavioral therapy (group-CBT) to medication would improve both the depressive
symptoms and the social functioning of patient with mild TRD, and whether any improvements would be
maintained over one year.
Methods: Forty-three patients with TRD were treated with 12 weekly sessions of group-CBT. Patients were
assessed with the Global Assessment of Functioning scale (GAF), the 36-item Short-Form Health Survey (SF-36), the
Hamilton Rating Scale for Depression (HRSD), the Dysfunctional Attitudes Scale (DAS), and the Automatic Thought
Questionnaire-Revised (ATQ-R) at baseline, at the termination of treatment, and at the 12-month follow-up.
Results: Thirty-eight patients completed treatment; five dropped out. For the patients who completed treatment,
post-treatment scores on the GAF and SF-36 were significantly higher than baseline scores. Scores on the HRSD,
DAS, and ATQ-R were significantly lower after the treatment. Thus patients improved on all measurements of
psychosocial functioning and mood symptoms. Twenty patients participated in the 12-month follow-up. Their
improvements for psychosocial functioning, depressive symptoms, and dysfunctional cognitions were sustained at
12 months following the completion of group-CBT.
Conclusions: These findings suggest a positive effect that the addition of cognitive behavioural group therapy to
medication on depressive symptoms and social functioning of mildly depressed patients, showing treatment
resistance.
Background
About 20 to 40% of depressed patients do not respond
satisfactorily to treatment with only antidepressant med-
ications [1-3]. These patients are defined as having
treatment-resistant depression (TRD) when they fail to
respond to at least two adequate trials of antidepressant
medications from different classes [3,4].
TRD patients frequently have impaired social func-
tioning because of sustained depressive symptoms [5].
The impairments affect marriages, cause interpersonal
problems, and difficulty in work environments [6]. Con-
tinued depression and psychosocial impairment may
induce social isolation, loneliness, and interpersonal dif-
ficulties that also interfere with the improvement of
depressive symptoms [7]. TRD patients who received
treatment as usual (TAU) with only medication contin-
ued to have functional disability [8].
Cognitive behavioral therapy (CBT) has been shown to
be effective in the treatment of major depressive disor-
der. DeRubeis et al. [9] suggested that CBT can be as
effective as medication for the initial treatment of mod-
erate to severe major depression. Other studies have
shown that adding CBT to medication for TRD may be
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ple, Thase et al. [10] compared the effectiveness of CBT
and medication as second-step strategies for the patients
with an unsatisfactory response to an initial trial of
medication (citalopram). They reported that those
patients who received CBT (either alone or in combina-
tion with citalopram) had similar response and remis-
sion rates to those who received only medication.
However, these studies have mainly investigated the
short-term effects of CBT on depressive symptoms. Sev-
eral studies investigated whether CBT improved social
functioning in individuals with chronic depression. Scott
et al. [11] assessed psychological and social functioning,
and compared medication management alone to CBT
plus medication management. They reported that
patients receiving cognitive therapy plus medication
management had better psychosocial functioning than
those who receiving medication management alone.
Hirschfeld et al. [12] studied patients who underwent a
cognitive behavioral analysis system of psychotherapy
(CBASP) as CBT for chronic depression, and compared
the efficacy of (1) CBASP, (2) nefazodone, or (3) CBASP
combined with nefazodone for improving psychosocial
functioning. They reported that the combined therapy
had greater effects than either monotherapy. These stu-
dies have been limited to consideration of the short-
term effectiveness of CBT for social functioning, and
they did not necessarily meet criteria for treatment
resistant.
Impaired social functioning may be a contributing
cause as well as an effect of depression in individuals
with TRD. Studies have not examined the effectiveness
of CBT, along with medication, for patients with TRD
with regard to both depressive symptoms and psychoso-
cial functioning, particularly with longer-term follow-up.
Therefore, we examined the short-term effectiveness of
combined therapy (group-CBT and medication) on not
only the depressive symptoms but the social functioning
of mild TRD patients. Moreover, we studied these long-
term effects (12 months) after the termination of group-
CBT. We addressed the following questions:
1. Is the combined therapy (group-CBT and medica-
tion) effective in improving not only the depressive
symptoms but the social functioning of patients with
treatment-resistant depression?
2. Are these effects of the combined treatment for
TRD maintained 12 months after termination of the
group-CBT?
Methods
Participants
A flow chart of participants is shown in Fig. 1. Forty-
three patients were recruited from the Department of
Psychiatry and Neurosciences at Hiroshima University
Hospital. Criteria for inclusion in the treatment study
were: (a) outpatients who could participate in the
group-CBT for 12 weeks, (b) a diagnosis of major
depressive disorder for the current episode established
by a psychiatrist or a clinical psychologist using the
Structured Clinical Interview for DSM-IV(SCID) [13,14],
(c) Hamilton Rating Scale for Depression (HRSD) [15]
score of 8 or greater, and (d) patients being defined as
the treatment resistant according to the staging system
of antidepressant resistance [4], with the level of the
treatment resistance at stage 2 or greater. Exclusion cri-
teria were: current or previous diagnosis of a psychotic
spectrum disorder, evidence of organic brain disorder,
mental retardation, personality disorder, current high
risk of suicide, substance abuse, or serious somatic dis-
ease. All patients were evaluated by a psychiatrist or a
clinical psychologist using the Structured Clinical Inter-
view for Axis I (SCID-I) [16] and the Structured Clinical
Interview for Axis II (SCID-II) [17].
All patients had previously taken two different classes
of antidepressant medications for a minimum of 8
weeks without remission of symptoms (some patients
had mild depressive symptoms): clomipramine (n = 13,
average 146 mg per day), paroxetine (n = 13, average 29
mg per day), milnacipran (n=1 3 ,a v e r a g e1 0 3m gp e r
day), or others. The drug type and dose was maintained
during the group-CBT treatment. We defined patients
whose medications were changed as dropouts. In addi-
tion, the patients did not take any other forms of treat-
ment except medication for the 12 months after the
group-CBT.
The study protocol was approved by the Ethics Com-
m i t t e eo ft h eH i r o s h i m aU n i v e r s i t yG r a d u a t eS c h o o lo f
Medical Sciences (Reference number: 628). Written
informed consent was obtained from all patients.
Measures
The patients were assessed using the following instru-
ments at pretreatment baseline, post-treatment, and 12
months after completion of the group-CBT.
a) Functioning assessment
The Global Assessment of Functioning (GAF: DSM-IV-
TR) [13,14] and the 36-item Short-Form Health Survey
(SF-36) [18,19] were used to measure social functioning
and quality of life. The GAF provides a rating of psycho-
logical, social, and occupational functioning on a
hypothetical continuum of mental health/illness rating
from 0 to 100. A rating higher than 70 indicates no
more than slight impairment in social, occupational or
school functioning.
The SF-36 is a 36-item questionnaire about functional
status and well being. The SF-36 is comprised of the
Physical Component Summary (PCS) and the Mental
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physical functioning, (2) role-physical factor in function-
ing, (3) bodily pain, (4) general health, (5) vitality, (6)
social functioning, (7) role-emotional factor in function-
ing, and (8) mental health. Each score ranges from 0 to
100, with 0 representing the poorest functioning and
100 representing optimal health. The Cronbach’sa l p h a
reliability estimates for the Japanese SF-36 are 0.71-0.87
for the subscales, indicating good test-retest reliability
[20].
b) Depressive symptoms assessment
The Hamilton Rating Scale for Depression (HRSD)
[15,21] is a 17-item scale used by the interviewing clini-
cian to assess the patient’s depressive symptoms. The
test-retest reliability correlation is 0.81, which indicates
adequate reliability [22].
c) Dysfunctional cognitions assessment
Dysfunctional cognitions were assessed by the Dysfunc-
tional Attitude Scale (DAS) [23,24] and the Automatic
Thought Questionnaire-Revised (ATQ-R) [25,26]. The
DAS is a 40-item self-report inventory designed to mea-
sure unstated assumptions and maladaptive beliefs often
found in depressed individuals. The Cronbach’sa l p h a
reliability estimate for the Japanese version is 0.86, con-
sistent with good test-retest reliability [24].
The ATQ-R is a 40-item self-report scale designed to
assess the levels of automatic thoughts. The ATQ-R
comprises both negative and positive thought scales.
The Japanese version has been tested in university stu-
dents. The Cronbach’s alpha reliability estimate of the
Japanese version has been reported as 0.94 for the nega-
tive thought scale and 0.88 for the positive thought
scale. Moreover, the sufficient reliability and construct
validity of the scale has been reported [26].
Treatment Procedures
Cognitive behavioral group therapy was conducted for
12 weekly 90-minute sessions; each group was com-
prised of five or six patients. The treatment was con-
ducted by two psychotherapists (one was a doctoral
level clinical psychologist with 12 years of experience,
the other was a doctoral student psychologist with 4
years of experience) and a psychiatrist with 10 years of
experience.
Treatment Protocol
The treatment program was based on research con-
ducted by Beck et al. [27]. The program consists of 12
structured sessions, as follows: (Session 1) Psycho-edu-
cation about depression; (Session 2) Psycho-education
about group-CBT; (Session 3) Instruction about self-
monitoring thinking, behavior, and mood; (Session 4)
Information about understanding the relationship
between cognition and mood; (Session 5) Identifying the
features of participants’ own negative thinking; (Session
6) Challenging one’so w nn e g a t i v et h i n k i n g ;( S e s s i o n7 )
Challenging and restructuring one’s own negative think-
ing; (Session 8) Looking for new ideas and invoking
positive thinking; (Session 9) Practicing the new ideas
and positive thinking in daily life; (Session 10) Evaluat-
ing one’s own ideas and thinking during the last week,
and setting up an action plan for the next week; (Ses-
sion 11) Reviewing the outcome of the program; (Ses-
sion 12) A lecture on relapse prevention. The treatment
program also used structured diaries and homework
assignments.
Statistical Methods
First we examined the differences between baseline and
post-treatment using an analysis of covariance
(ANCOVA) that controlled for the baseline levels of
variables. We calculated the improvement effect sizes
[partial h
2 = F * dftime/F * dftime + dferror] [28]. Accord-
ing to conventional criteria a partial h
2 of 0.01 is small,
0.06 is moderate, and 0.14 is large. Statistically signifi-
cant differences were evaluated with paired t-tests
(using a Bonferroni correction). If there were statistically
significant differences, we also computed Cohen’s d as a
measure of the pre-post effect size. According to the cri-
teria of Cohen’s classification a d of 0.2 is small, 0.5 is
medium, and 0.8 is large [29].
Next, we calculated the remission and response rates
after the completion of the group-CBT. Remission was
defined as a score of 7 or less on the HRSD. A positive
treatment response was defined as a 50% or greater
reduction in the HRSD score compared to the pre-treat-
ment score. We also calculated the reliable change and
clinically significant chan g eo fd e p r e s s i v es y m p t o m s
using Jacobson and Truax’s( J T )m e t h o d ,w h i c hu s e s
two steps [30,31]. The first step is to define a cutoff
point that separates the functional population from the
dysfunctional population. The cutoff we used point was
± 2 SD from the pre-treatment mean. The second step
compares an individual’s change from pre- to post-treat-
ment to a standard error of measurement of the out-
come, referred to as the Reliable Change Index (RCI). If
the RCI is higher than 1.96, the probability that the pre-
post treatment difference occurred by chance is less
than 5%. Using the results of these two steps, we classi-
fied patients into three categories: recovered (passed
cutoff point and RCI >1.96), improved (did not pass cut-
off point but RCI >1.96), or unchanged or deteriorated
(passed neither criterion).
Finally, we analyzed the follow-up data using repeated
measures ANCOVA for each outcome measurement
(assessed at pre-treatment, post-treatment, and 12
months after group-CBT), and calculated improvement
effect sizes. We performed repeated measures ANCOVA
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significant comparisons, we conducted post hoc paired
t-tests using a Bonferroni correction.
All analyses were conducted on intent-to-treat (ITT)
and completed treatment (Completer) samples. In the
ITT analyses, the missing post-treatment or follow-up
data were considered to be non-responders or adverse
events, and their last available observations were carried
forward (LOCF: last observation carried forward).
All statistical tests were two-tailed, with an alpha level
of 0.05. All the data were examined using SPSS for Win-
dows, version 16.0.
Results
Clinical backgrounds
Table 1 shows the demographic and clinical characteris-
tics of the 43 patients enrolled in the group-CBT. There
were 24 men and 19 women, mean age 41.3 years; 28
were married. The majority of patients had had more
than 13 years of education (77%). The patient’sa v e r a g e
duration of depressive illness was 19.4 ± 15.6 months.
Eighteen patients had not responded after treatment
with two or more antidepressants with different action
mechanisms (stage 2), and 25 patients (stage 3) had
failed treatment with tricyclic antidepressants in addi-
tion to stage 2 criteria. Eighteen (42%) were experien-
cing their first depressive episode. The baseline scores
on the Hamilton Rating Scale for Depression (HRSD)
indicated mild to moderate levels of depression among
the patients (Mean = 14.7, SD =4 . 4 ) .S e v e np a t i e n t s
(16%) had HRSD scores between 8 and 10, 13 (30%) had
scores between 11 and 14, 13 (30%) had scores of
between 15 and 18, and 10 (23%) had scores between 18
and 27. The baseline GAF scores indicated a poor level
of social functioning. 31 patients (72%) had scores
between 40 and 60, and the other 12 (28%) had scores
between 61 and 70.
Of the 43 patients who began the group-CBT, 38
completed the program and 5 dropped out. Four drop-
outs were due to worsening symptoms, and the fifth was
dissatisfied with the program. The ITT sample is the
total initial patient sample of 43, while the Completer
sample is the 38 patients who completed the group-
CBT. The demographic and clinical characteristics did
not differ between those who completed the group-CBT
and those who did not.
Acute treatment outcomes
a) Functional status
Table 2 displays the results of ANCOVAs for the GAF
and Short-Form Health Survey (SF-36) scores from pre-
to post-treatment. For both the ITT and Completer ana-
lyses, the GAF scores increased significantly (ITT: F (1,
83) = 40.06, p < 0.001, partial h
2 =0 . 3 3 ,C o h e n ’s d =
0.94; Completer: F (1, 72) = 41.19, p < 0.001, partial h
2
= 0.53, Cohen’s d = 1.24). For the ITT sample, the num-
ber of patients who were rated as showing mild func-
tional impairment (defined as GAF scores over 60)
improved from 12 (28%) at baseline to 30 (70%) at post-
treatment; 7 (16%) of these patients were rated as having
minimal impairment (GAF > 70). As expected, the
Completer sample comprised those 30 patients who had
a post-treatment GAF score over 60 (79%), and the 7
patients (18%) who were rated as having minimal
impairment (GAF > 70).
On the SF-36, the physical health (PCS) and mental
health (MCS) scores at post-treatment were higher than
at baseline, for both the ITT and Completer samples (all
p values < 0.01). The effect sizes of the MCS improve-
ment were greater than these for the PCS, indicating
that the group-CBT was more strongly associated with
improvement in mental health than physical health.
Seven of the 8 subscale scores were improved signifi-
cantly (bodily pain was not). The pre-post effect sizes
(Cohen’s d) for the vitality (ITT: 0.90; Completer: 1.08)
and mental health (ITT: 0.83; Completer: 0.95) subscales
were especially larger than for the other subscales.
b) Depressive symptoms
ANCOVA for the Hamilton Rating Scale for Depression
(HRSD) scores showed a highly significant time effect.
For the ITT sample, the mean HRSD scores decreased
Table 1 Baseline demographic and clinical characteristic
(N = 43)
N%
Female 19 44.2
Age at intake, mean(SD), year 41.3 (9.2)
Employ status
Employed 1 2.3
Absence from work 31 72.1
Unemployed 11 25.6
Marital status
Single 15 34.9
Married 28 65.1
Education, mean (SD), year 14.9 (1.9)
Diagnosis
Single episode 18 41.9
Recurrent 25 58.1
Treatment-resistant depression level
TRD level II 18 41.9
TRD level III 25 58.1
Number of episode, median (range) 2 (1-4)
Duration of the current episode, mean (SD) 19.4 (15.6)
HRSD score, mean (SD) 14.7 (4.4)
GAF score, mean (SD) 59.5 (6.1)
HRSD: Hamilton Rating Scale for Depression
GAF: Global Assessment of Functioning scale
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(F (1, 83) = 42.23, p < 0.001, partial h
2 = 0.34, Cohen’s
d = 1.09). For the Completer, the mean HRSD scores
decreased from 14.2 at pre-treatment to 8.2 at post-
treatment (F (1, 73) = 53.29, p < 0.001, partial h
2 = 0.42,
Cohen’s d = 1.30). Among the Completers, 21 (55%) of
the patients had scores of 7 or less on the HRSD at
post-treatment. 12 had scores between 8 and 14, and 5
had scores between 15 and 21.
Table 3 shows the remission and response rates at
post-treatment for the ITT and Completer sample ana-
lyses. Twenty-one participants (ITT: 49%; Completer:
55%) met criteria for remission (HRSD score of 7 or
less), and 18 participants (ITT: 42%; Completer: 47%)
showed at least a 50% reduction of their scores on the
HRSD from the pre-treatment score. The number of
participants who met criteria both for remission and
50% reduction of were 17 (ITT: 40%; Completer: 45%).
In addition, we calculated the reliable change and clini-
cally significant change using Jacobson and Truax’sf o r -
mula [30]. For the ITT sample, the cutoff point on the
HRSD was 5. The criteria for “recovered” were fulfilled
by 9 (21%) participants, 10 (23%) were “improved”,a n d
24 (56%) were “unchanged” or “deteriorated”. Among the
38 patients who completed the treatment, the cutoff
point on the HRSD was 6. Nineteen (50%) met criteria
for “recovered” or “improved”, and the other 19 (50%)
were classified as “unchanged or deteriorated”.
c) Dysfunctional cognitions
The score on the Dysfunctional Attitude Scale (DAS)
decreased significantly from pre-treatment to post-
Table 2 ANCOVAs of treatment outcome as measured by GAF and SF-36
pre Mean(SD) post treatment Mean(SD) F value effect size partial Eta
2 d
ITT(N = 43)
GAF 59.49(6.10) 65.51(6.68) 40.06*** 0.33 0.94
SF-36 PCS 41.00(11.12) 46.78(10.22) 16.31*** 0.16 0.54
Physical functioning 76.33(17.38) 84.77(15.92) 16.49*** 0.17 0.51
Role physical 27.33(42.19) 58.14(42.86) 5.14* 0.06 0.72
Bodily pain 61.58(25.68) 68.45(26.94) 4.08* 0.05 0.26
General health 38.66(15.76) 48.74(20.36) 5.73* 0.07 0.00
SF-36 MCS 25.77 (8.70) 33.52(10.97) 25.17*** 0.23 0.78
Vitality 24.65(13.69) 39.65(19.32) 11.58** 0.12 0.90
Social functioning 43.84(20.79) 59.59(23.75) 16.15*** 0.16 0.71
Role emotional 11.63(28.06) 34.88(39.14) 19.06*** 0.19 0.68
Mental health 37.86(15.82) 52.09(18.34) 30.24*** 0.27 0.83
Completer (N = 38)
GAF 60.18(5.79) 67.00(5.17) 41.19*** 0.53 1.24
SF-36 PCS 41.18(11.04) 47.72(9.62) 17.73*** 0.20 0.63
Physical functioning 77.43(16.65) 86.97(13.78) 26.38*** 0.27 0.62
Role physical 23.68(41.08) 58.55(43.21) 47.11*** 0.40 0.83
Bodily pain 62.68(26.63) 70.46(27.55) 4.15* 0.05 0.29
General health 38.62(16.03) 50.03(20.76) 13.23** 0.15 0.62
SF-36 MCS 25.93 (8.95) 34.71(10.90) 27.53*** 0.27 0.88
Vitality 24.87(12.81) 41.84(18.25) 34.89*** 0.32 1.08
Social functioning 44.34(21.83) 62.17(23.87) 17.21*** 0.19 0.78
Role emotional 11.40(29.28) 37.72(40.40) 20.19*** 0.22 0.75
Mental health 38.00(16.10) 54.11(17.93) 33.73*** 0.32 0.95
** p < .001, ** p < .01, * p < .05
GAF: Global Assessment of Functioning scale
SF-36: 36-item Short-Form Health Survey
PCS: Physical Component Summary
MCS: Mental Component Summary
Table 3 Remission and response rates after group-CBT
Outcome Criteria N %
Remission
HRSD score
≦7 ITT (N = 43)
21 48.8
HRSD score
≦7 Completers (N = 38)
21 55.3
Response
HRSD score reduction of
≧50% ITT (N = 43)
18 41.9
HRSD score reduction of
≧50% Completers (N = 38)
18 47.4
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mean of the DAS scores changed using the LOCF (last
observation carried forward) method from 161.3 to
147.6 (F (1, 83) = 17.13, p < 0.001, partial h
2 = 0.29,
Cohen’s d = 0.17). The mean for the 38 in the Comple-
ter sample decreased from 156.3 to 140.9 (F (1, 73) =
18.42, p < 0.001, partial h
2 = 0.20, Cohen’s d = 0.48).
In addition, the means on the ATQ-R negative scale at
post-treatment were significantly lower than the means
at pre-treatment using the same two methods of analy-
sis. The mean of the ATQ-R negative scale scores chan-
ged using the LOCF method from 90.0 to 70.8 (F (1, 83)
= 39.09, p < 0.001, partial h
2 =0 . 3 2 ,C o h e n ’s d = 0.76).
The mean for the 38 in the Completer sample decreased
from 87.2 to 65.5 (F (1, 73) = 50.61, p < 0.001, partial h
2
= 0.41, Cohen’d = 1.00). However, there was no signifi-
cant difference on the ATQ-R positive scale between
pre-treatment and post-treatment in the ITT or Com-
pleter sample analyses.
A 12-month follow-up outcome
Of the 38 patients who completed the group-CBT, a
total of 28 patients had completed the treatment more
than one year previously at the time of our follow-up.
The remaining 10 persons had completed the group-
CBT were less than one year previously at the time of
our follow-up. Twenty of the 28 patients (71%) com-
pleted all measurements one year after finishing the
group-CBT; the other 8 refused to participate in the fol-
low-up (4 refused the participation in the follow-up
study, and 4 refused accesses to contact for follow-up).
We analyzed the follow-up data using both the ITT
and Completer samples. For the ITT analysis which
included 12 dropouts (4 who did not complete the treat-
ment, and 8 who refused the follow-up study), the last
observation values were carried forward (LOCF). We
excluded one patient who dropped out from the ITT
samples because the patient had not passed for one year
at the time of the follow-up assessment. Table 4 shows
the changes in functional status measured by the GAF
and SF-36 for the ITT and Completer samples. The
repeated measures ANCOVAs for GAF revealed a sig-
nificant time effect for the both the ITT sample and
Completer samples (both p value < 0.001). Post hoc
paired t-tests with a Bonferroni correction showed that
the score at post-treatment was higher than the score at
Table 4 Repeated measure ANCOVAs of 12-month follow-up measured by GAF and SF-36
Pre-treatment Mean (SD) Post-treatment Mean (SD) 12 months Mean (SD) F value effect size partial Eta
2
ITT (N = 32)
GAF 60.62(6.36) 66.41(6.74)
a 71.22(9.16)
b, c 21.44*** 0.32
SF-36 PCS 42.23 (8.88) 48.21 (9.78)
a 46.97 (9.34)
b 6.71** 0.13
Physical functioning 76.87(16.84) 84.53 (14.67)
a 84.53 (14.11)
b 8.28*** 0.15
Role physical 21.88(39.53) 60.16 (45.73)
a 59.38 (40.54)
b 11.39*** 0.20
Bodily pain 65.84(22.56) 70.73 (25.29) 74.06 (24.06) 1.87 0.04
General health 39.78(14.92) 51.13 (20.59)
a 49.91 (19.64)
b 5.19** 0.10
SF-36 MCS 26.16 (9.70) 33.59 (11.20)
a 38.34 (11.63)
b 15.32*** 0.25
Vitality 26.41(14.66) 40.31 (19.10)
a 43.75 (19.76)
b 12.59*** 0.22
Social functioning 44.84(21.91) 60.55 (23.14)
a 68.75 (25.79)
b 10.51*** 0.19
Role emotional 13.54(31.52) 37.50 (42.12)
a 54.17 (43.79)
b 13.07*** 0.22
Mental health 38.13(16.51) 51.63 (18.16)
a 55.83 (18.80)
b 13.18*** 0.22
Completers (N = 20)
GAF 60.24 (6.86) 66.48 (6.40)
a 73.81 (7.29)
b, c 25.99*** 0.48
SF-36 PCS 43.80 (8.48) 50.32 (7.88)
a 48.18 (7.28) 5.10** 0.15
Physical functioning 80.25(13.13) 89.50 (9.02)
a 89.00 (7.88)
b 12.31*** 0.31
Role physical 21.25(40.78) 57.50 (47.37)
a 56.25 (38.79)
b 5.75** 0.17
Bodily pain 66.60 (24.30) 73.28 (27.40) 76.30 (26.75) 1.34 0.05
General health 39.55 (16.17) 55.90 (22.06)
a 54.10 (21.19)
b 6.94** 0.27
SF-36 MCS 25.23 (9.77) 33.78 (11.06)
a 40.56 (10.71)
b, c 13.91*** 0.33
Vitality 25.50 (13.66) 42.25 (16.58)
a 47.25 (17.66)
b 10.78*** 0.28
Social functioning 48.00 (21.86) 61.87 (26.12) 73.13 (29.32)
b 8.69** 0.24
Role emotional 13.33 (33.16) 40.00 (45.37) 63.33 (45.76)
b, c 11.23*** 0.29
Mental health 34.80 (16.68) 52.00 (16.57)
a 57.60 (17.38)
b 15.00** 0.35
*** p < .001, ** p < .01, * p < .05
a: significant difference between Pre- and Post-treatment (p < .05)
b: significant difference between Pre- and 12 months after treatment (p <. 0 5 )
c: significant difference between Post- and 12 months after treatment (p <. 0 5 )
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Page 7 of 10baseline, and the score at the 12-month follow-up was
also higher than at the post-treatment (p < 0.001). For
the ITT sample, including the 12 dropouts, 27(84%) met
criteria for the mild-minimal impairment (GAF < 60),
and 12 patients (38%) reached the level of functioning
well. For the Completer sample, except for one patient,
all patients (95%) were at the mild-minimal impairment
level (GAF < 60), and 10 patients (50%) were function-
ing well (GAF > 70) at the 12-month follow-up.
The repeated measures ANCOVAs for the SF-36
(both PCS and MCS) also showed significant time
effects for both the ITT samples and the Completer
samples (all p values < 0.01). Post hoc paired t-tests
with a Bonferroni correction demonstrated that MCS
scores at post-treatment and at 12-month follow-up
were higher than the baseline score in the Completer
analysis (p < 0.001). However, in the ITT analysis, MCS
score at follow-up was not significantly difference from
that at post-treatment. Regarding the subscale scores, 7
of the 8 subscale scores at the 12-month follow-up were
significant higher than the baseline scores (bodily pain
was the exception).
Regarding depressive symptoms, in both the ITT and
Completer analyses, there was a significant change in
the Hamilton Rating Scale for Depression (HRSD) score
during the 12-month follow-up (both p values < 0.001),
with the score at the follow-up being lower than the
score at baseline (ps < 0.001). For the ITT sample, 22
patients (69%) had scores of 7 or less on the HRSD at
the 12-month follow-up. 8(25%) had scores between 8
and 14, and other two had scores between 15 and 22.
Of the 20 in the Completer sample, 14 (70%) had scores
o f7o rl e s so nt h eH R S Da tt h e1 2 - m o n t hf o l l o w - u p .
Five (25%) had scores between 8 and 14, and one scored
22.
Additionally, dysfunctional cognitions measured by the
DAS and the ATQ-R negative scales showed sustained
improvements in both the ITT and Completer analyses
(all p values < 0.05). However, there was no significant
change on the ATQ-R positive scale in the ITT or Com-
pleter sample analyses.
Discussion
We examined the efficacy of the adding cognitive beha-
vioral therapy to treatment with medication for improv-
ing both the depressive symptoms and the social
functioning of TRD patients. The baseline scores on the
HRSD in the present study were in the mild to moder-
ate depression range. However, psychosocial functioning
in the majority of patients was poor. The mean of the
enrolled patients’ depressive episode at the baseline was
19.4 months, which indicated that their depressive
symptoms and psychosocial functioning impairments
had existed for long term. The cognitive behavioral
therapy combined with medication for the patients with
TRD resulted in significant improvement in both the
depressive symptoms and the social functioning of the
patients, and maintained improvement after a one year
f o l l o w - u p .A sf a ra sw ek n o w ,t h i si st h ef i r s ts t u d yt o
investigate the long term effectiveness of adding cogni-
tive behavioral therapy to medication for improving
both depressive symptoms and social functioning of
patients defined as TRD.
Few previous studies have investigated the social func-
t i o n i n go fp a t i e n t sw i t hT R D .D u n n e re ta l .[ 8 ]a s s e s s e d
the social functioning of TRD patients (N = 124), using
the SF-36 with treatment as usual (TAU) over two
years. They reported that the scores on the PCS and
MCS scales of the SF-36 did not change over the two
years. In the present study, the PCS and MCS scores
were similar at baseline to the results of Dunner et al.
[8], but these scores in our study showed sustained
improvement, especially for the mental components
(MCS), after CBT treatment and one year later. For
example, the MCS score at 12 months in the Dunner et
al. [8] study was 27.8, while in our study it was 40.6. In
combination with the findings of Dunner et al., these
findings indicate a possibility that combining cognitive
behavioral group therapy with medication improves
social functioning more than TAU. In our study, the
v i t a l i t ys u b s c a l ea n dt h em e n t a lh e a l t hs u b s c a l es c o r e s
were especially increased. The improvements support
the hypothesis that CBT may be promoting an improve-
ment in energy or vitality via an increase in overall
activity level [32].
In recent years, social functioning has become of
increasing importance in the treatment and outcome
assessment of psychiatric disorders. Some researchers
have suggested that a broader definition of remission is
needed - one that involves not only the absence of
symptoms but also improvement in psychosocial func-
tioning [33,34]. They emphasize that the improvement
in psychosocial functioning may be necessary not only
to prevent relapse but also to ensure full remission of
t h ed i s o r d e r .A tt h es a m et i m e ,i n t e r e s ti nC B T
approaches as an effective intervention to improve psy-
chosocial recovery is also increasing. There are trials of
CBT focused on social functioning in individuals with
bipolar disorder [32], bulimia nervosa [35], and psycho-
sis [36]. In the case of chronic depression, several stu-
dies reported the short-term effectiveness of CBT in
improving social functioning [11,12]. It is likely that
chronic depression in these studies included treatment-
resistant depression. Our study indicates that the
improvements in social functioning are sustained over
one year after CBT.
Our protocol used basic CBT strategies, and did not
include social skills training or stress management.
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Page 8 of 10However, the patients learned appropriate cognitive and
behavioral coping strategies for increasing meaningful
activity and managing interpersonal stress [32,37]. The
group-CBT provided both social support and also mod-
eling effect [38,39]. The group format provided patients
with opportunities for practicing new cognitive and
behavioral skills, which they could apply in their lives
after completion of the group-CBT [39]. These cognitive
and behavioral skills may have influenced the improve-
ment of social functioning.
Regarding depressive symptoms, about 50 to 55% of
the participants who completed the group-CBT sessions
achieved remission after the completion of treatment
(HRSD score of 7 or less), and about 40 to 50% of the
participants were judged to be responders (HRSD score
decreased by 50%). In terms of the clinical significant
change [30], half of the patients showed recovery or
improvement. These results are similar to the outcomes
in previous studies (e.g. Fava et al.; Moore & Blackburn;
Thase et al.) [10,40,41].
This study has several limitations. First, the lack of a
control group limits the interpretation of the results. It
remains unknown whether the improvement in social
functioning with TRD is related to natural course of
depression. In addition, it is not clear whether the group
affiliation or the CBT strategy is the active factor
accounting for the improvements. More research using a
TAU (treatment as usual) control group or different
treatment groups is needed. Second, most TRD patients
in the present study were less severely depressed than in
previous studies of patients with TRD [11,12,40],
although they met diagnostic criteria for mild to moder-
ate depression. So we do not know whether the findings
of this study can be generalized to patients with severe
TRD. Third, there were missing data from people who
did not complete treatment. We used not only the com-
pleter analyses but also the ITT analyses. Although the
results did not differ much between the dropouts
(included in the ITT sample) and the treatment comple-
ters, there were some patients who did not complete
group-CBT because they got worse. Also, control of the
specific antidepressants could not be implemented in our
longitudinal study. Therefore, the results of maintaining
improvement may include some effects of medication.
Despite these limitations, the present study suggests
that using group-CBT along with medication has a posi-
tive effect on both depressive symptoms and psychoso-
cial functioning, a suggestion that needs to be
confirmed in larger samples using randomized con-
trolled trials.
Conclusions
This study suggests a positive effect that combining cog-
nitive behavioral therapy with medications improves
both depressive symptoms and social functioning with
TRD. Moreover, these improvements in both depressive
symptoms and social functioning were maintained over
one year following completion of CBT while continuing
on medication.
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